Related Experiment Videos
Screening novel, potent multidrug-resistant modulators from imidazole derivatives
Li-ming Chen1, Xing-Ping Wu, Ji-wu Ruan
1Cancer Center, Sun Yat-Sen University, Guangzhou, P R China.
Oncology Research
|August 11, 2004
Summary
New imidazole derivatives, FG020326, FG020327, and FG020318, show potent multidrug resistance (MDR) reversal activity. These compounds inhibit P-glycoprotein (P-gp) function, enhancing anticancer drug accumulation in resistant tumor cells.
Area of Science:
- Pharmacology and Oncology
- Medicinal Chemistry
Background:
- Overexpression of P-glycoprotein (P-gp) in tumor cells leads to multidrug resistance (MDR), limiting the efficacy of anticancer therapies.
- Combined therapeutic strategies involving MDR modulators are crucial for overcoming clinical MDR.
Purpose of the Study:
- To screen imidazole derivatives for potent MDR modulators.
- To evaluate the efficacy of identified compounds in reversing P-gp-mediated MDR.
Main Methods:
- Cytotoxicity assessed using MTT assay.
- Intracellular doxorubicin (Dox) accumulation measured via fluorescence spectrophotometry.
- P-glycoprotein (P-gp) function evaluated by Rhodamine 123 accumulation using flow cytometry (FCM).
Main Results:
- FG020326, FG020327, and FG020318 demonstrated 3-4 fold greater MDR reversal activity than verapamil.
- These imidazole derivatives significantly enhanced Dox accumulation and inhibited P-gp function in MDR cells.
- Increased Rhodamine accumulation correlated with the fold reversal of MDR.
Conclusions:
- FG020326, FG020327, and FG020318 exhibit potent in vitro MDR reversal activity.
- Their mechanism involves inhibiting P-gp function and increasing anticancer drug accumulation.
- These compounds represent promising candidates for further development in overcoming MDR.